Compare MC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | ARQT |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2014 | 2020 |
| Metric | MC | ARQT |
|---|---|---|
| Price | $68.02 | $23.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $72.88 | $34.00 |
| AVG Volume (30 Days) | ★ 1.0M | 973.7K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $18.28 | $34.85 |
| Revenue Next Year | $17.22 | $29.39 |
| P/E Ratio | $89.08 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $51.06 | $12.42 |
| 52 Week High | $78.22 | $31.77 |
| Indicator | MC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 71.42 | 45.73 |
| Support Level | $60.61 | $22.56 |
| Resistance Level | $73.46 | $23.46 |
| Average True Range (ATR) | 2.30 | 0.89 |
| MACD | 0.60 | -0.06 |
| Stochastic Oscillator | 83.84 | 25.17 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.